Printed From BioPortfolio.com
Pacific Edge (PEB) - Anticipating commercial growth
03:23 EST 9 Jan 2018 | Edison Investment Research
Edison Investment Research - Pharmaceutical & healthcare - Pacific Edge: Pacific Edge continues to make progress commercialising its suite of bladder cancer diagnostics products, with three tests currently available in the US market. An uplift in sales is expected as TRICARE and the Veterans Administration (VA) are under contract, although the exact timing of a sales ramp is unknown. In addition, the company’s discussions with Kaiser Permanente are nearing a final decision and progress has been made with achieving inclusion in the local coverage determination (LCD) by the US Centers for Medicare and Medicaid Services (CMS).
ISIN: NZPEBE0002S1
Original Article: Pacific Edge (PEB) - Anticipating commercial growth
